Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction
- 17 December 2001
- journal article
- other
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Cardiology
- Vol. 104 (25), 3063-3068
- https://doi.org/10.1161/hc5001.100793
Abstract
Background — It is pathophysiologically conceivable that genetic variations in coagulation and fibrinolytic proteins are associated with the risk of myocardial infarction. Methods and Results — We performed a literature search to identify published case-control studies correlating the factor V Leiden or prothrombin G20210A mutations or fibrinogen G−455A or plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphisms with the risk of myocardial infarction. Studies were included only if they used solid diagnostic criteria and complied with published methodological criteria. A common OR with corresponding 95% CI was calculated for the risk of myocardial infarction in a fixed-effect model according to Mantel-Haenszel. The factor V Leiden and prothrombin G20201A mutations did not significantly correlate with myocardial infarction (OR 1.26, 95% CI 0.94 to 1.67, P =0.12 and OR 0.89, 95% CI 0.59 to 1.35, P =0.6, respectively). Inclusion of the studies that investigated young patients (P =0.02). Homozygosity for the fibrinogen −455A allele was significantly associated with a decreased risk of myocardial infarction (OR 0.66, 95% CI 0.44 to 0.99, P =0.04), whereas the PAI-1 4G4G genotype was significantly associated with increased risk (OR 1.20, 95% CI 1.04 to 1.39, P =0.04). Conclusions — Associations between these genetic variations and myocardial infarction were weak or absent. In the absence of clinical implications, our results indicate that screening of patients with myocardial infarction for these genetic variations is not warranted.This publication has 34 references indexed in Scilit:
- The Role of the t-PA I/D and PAI-1 4G/5G Polymorphisms in African-American Adults With a Diagnosis of Myocardial Infarction or Venous ThromboembolismThrombosis Research, 2000
- Plasminogen Activator Inhibitor 4G Polymorphism Is Associated With Decreased Risk of Cerebrovascular Mortality in Older WomenJournal of the American College of Cardiology, 2000
- Clinical Epidemiological Quality in Molecular Genetic ResearchJAMA, 1999
- Factor V Arg506Gln Mutation Is Not Associated with Cardiovascular Mortality in Older WomenAmerican Journal of Epidemiology, 1999
- Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young menBlood Coagulation & Fibrinolysis, 1998
- Prevalence of the prothrombin gene variant 20210 G→A among patients with myocardial infarctionCardiovascular Research, 1998
- A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study.JCI Insight, 1997
- Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countriesJournal of Internal Medicine, 1996
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenThe New England Journal of Medicine, 1995
- Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.Proceedings of the National Academy of Sciences of the United States of America, 1995